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SUMMARY 
A non-linear relationship between the percent aggregation of human 
platelets and the amount of TXB 2 generated requires investigators to 
use caution when using the data to assess antiplatelet regimens. The 
relationship approximates a hyperbola with a roughly linear relationship 
from 0 to 70% aggregation and 0 to 50 ng TXB 2 per ml of platelet-r ich 
plasma. Above these values, the amount of TXB 2 produced may increase 
up to 500 ng per ml of platelet-r ich plasma with no clear relationship to 
the observed platelet function of aggregation. Also, appreciable 
inhibi t ion of TXB 2 formation can occur at high TXB 2 levels with no 
detectable decrease in aggregation. Thus, assessment of antiplatelet 
regimens using TXB 2 formation alone are unlikely to be interpretable 
without reference to this non-linear property of platelet function. We 
applied this concept when evaluating a study of forty subjects with 
dietary supplements of 1.8 g or 2.7 g of ethyl eicosapentaenoate 
(20:5n-3) for four weeks. There was a moderate, but s ta t i s t i ca l l y  
signif icant decrease in average values for the percent aggregation (60±15 
to 45±30) and thromboxane production (51±30 to 33±31 ng/ml). Although 
the differences in mean values were sl ight relative to the overall 
standard deviations, reductions of platelet function were clearly evident 
in 31 of 40 subjects when paired results were examined relative to the 
recognized hyperbolic relationship. 
INTRODUCTION 
A report at the 1983 Winter Prostaglandin Conference described a mean 
difference in platelet function between control and experimental subjects 
receiving fish o i l  that was of small magnitude, but s ta t i s t i ca l l y  
signif icant. In evaluating these results, we realized that a large 
standard deviation in the results was in part due to an experimental 
phenomenon that obscured the changes occurring. Our three laboratories 
had independently encountered d i f f i cu l t y  in obtaining a simple 
relationship between the amount of thromboxane generated and the expected 
or observed amount of aggregation. Each had results that were non-linear 
and seemed to be either uninterpretable or unreliable. In reviewing the 
problem col lect ively, we jo in t l y  realized that we had a common discovery 
that had not been previously communicated concerning the overall 
relationship between these two variables. This report provides a summary 
of our insight into this relationship to help investigators recognize the 
l imits of l inear i ty  that can be expected for platelet aggregation and 
thromboxane formation. Our collective experience is provided to 
demonstrate the region of submaximal platelet response that is most 
useful for interpretive studies. 
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MATERIALS AND METHODS 
Platelet Aggregation (University of Michigan) 
Human whole blood was obtained from healtl~y volunteers who had not 
consumed any medications for lO days prior to pheresis at the University 
of Michigan Medical Center Blood Bank or hematology laboratory. Platelet 
rich plasma (PRP) was prepared by differential centrifugation. The PRP 
was stored at 220C for the platelet storage study. 
Platelet aggregation was studied by modifications of commonly-used 
spectrophotometric methods (1) ut i l iz ing a Sienco Dual Sample 
Aggregometer DP-247E (Sienco, Inc. Morrison, Colorado). Platelets were 
counted on a Haema-Count TM MK-4/HC (3.T. Baker Instruments, Milford, 
Conn.) and platelet-rich plasma was adjusted to 2 x lO8/ml platelets 
before testing. Baseline for 0 and lO0 light transmission were set with 
PRP and PPP, respectively, silicone-coated s t i r  bars l x 5 mm were added 
to siliconized glass curvettes at 37°C and s t i r  speed adjusted to lO00 
rpm. Aggregation of platelets with "soluble" bovine deep flexortendon 
(2.2, lO, 22, and lO0 ug/ml; Ethicon, Sommerville, N.3.) was seen as an 
increase in percent l ight transmission. 
Platelet Ag~reqation (Chiba University) 
Platelet aggregation was measured according to the method of Born 
(1), with a "Sienco" dual channel aggregometer DP247E (Morrison, CO). 
Citrated venous blood was obtained and immediately centrifuged at 150 x g 
for lO min at room temperature to obtain platelet-rich plasma (PRP). The 
residual blood was further centrifuged at 1800 x g for 15 min to obtain 
platelet-poor plasma (PPP). The platelet count of PRP was adjusted to 4 
x lO8/ml with autologous PPP. The aggregation was carried out with 
st irr ing at lO00 rpm at 37.5°C within 120 min of venipuncture. The 
change in l ight transmission after the addition of collagen (l.O and 1.5 
~g/ml) was recorded as a percentage, and aggregation was expressed as the 
maximum increase in light transmission in 5 min. 
Thromboxane B 2 Radioimmunoassay (University of Michigan) 
Samples of plasma and p l a t e l e t - r i c h  plasma (PRP) were t reated with 
a c e t o n i t r i l e  ( I : I ) .  The supernatant was removed and a c i d i f i e d  to pH 3.5 
with formic acid fol lowed by two 3 ml ext ract ions with petroleum ether. 
The aqueous f rac t i on  was then extracted twice with 4 ml of ethyl  
acetate. The combined ethyl  acetate layers were evaporated to dryness 
under ni t rogen and dissolved in the assay buf fer  (0. I  M phosphate- 
buffered sa l ine ,  pH 7.4 containing 0.1% g e l a t i n ) .  T r i t i a t e d  
thromboxane B 2 was added before ex t rac t ion  to monitor recoveries. Each 
sample was assayed in dupl icate  in at least  two d i l u t i o n s .  T r i t i a t e d  
thromboxane B 2 was added to samples and standards, fol lowed by 
antiserum. The f i n a l  d i l u t i o n  of antibody was 1:14,000 and assay volume 
was 0.3 ml. Tubes were vortexed and incubated at 25 ° C (room 
temperature) fo r  1 hour and then at 4 ° C fo r  16 to 24 hours. The 
separation of the ant ibody-ant igen complex from free antigen was achieved 
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by adsorption of the free t r i t ia ted thromboxane B 2 on to cold activated 
dextran-coated charcoal. (Norit A, 250 mg; Dextran T-70, 25 mg/lO0 ml 
buffer.) 
Following centrifugation, the supernatant containing the 
antlgen-antibody complex was decanted from the hard charcoal pellet 
containing the free antigen. The supernatant was transferred to a 
scint i l la t ion vial containing lO ml of Scintisol (Amersham Searle, Des 
Plaines, IL) counting f lu id.  
Radioactivity was determined to a I% error in a Beckman Beta 
Spectrometer (Beckman Instrument Co., Irvine, CA) with an overall 
efficiency of 40%. The binding data (B/Bo) was calculated for each 
sample and the concentration of each sample was determined from standard 
curves. 
Thromboxane B2 Formation (Chiba University) 
Thromboxane B 2 (TXB2) formation by platelets was determined by 
radioimmunoassay in connection with the platelet aggregation study as 
previously reported (2). After 5 min of aggregation induced by collagen 
or epinephrine, lO0 ~I of aggregated PRP was transferred to a plastic 
tube containing 200 gl of 50 mR Tris-HCl buffer, pH 7.5 with I% 
gelatin. This tube was immediately dipped into liquid nitrogen for lO 
sec and stored at -800C until the assay of TXB 2 by radioimmunoassay 
(TXB 2 [3H]RIA Kit, New England Nuclear, Boston). The extraction of 
TXB 2 from the reaction mixture was performed by the method of Green et 
al. (3) with minor modifications. The recovery of TXB 2 was around 
75%. The cross reactivi ty of the RIA Kit antibody was 0.2~ for 
Prostaglandin (PG) E 2 and less than 0.2% for PGA 2, PGF2= and 
6-Keto PGFI=. 
Subjects and Study Design (Chiba University) 
Forty patients (20 male and 20 female, average age of 59 years) 
diagnosed as having diabetes mellitus, cerebrovascular disorders, 
ischemic heart diseases, hyperlipidemia Type IIa, IIb and IV and 
hypertension were used in the present study. Any medication affecting 
platelet aggregation was discontinued at least 2 weeks prior to the start 
of the study. 
The encapsulated ethyleicosapentaenoate (EPA-E) was provided by 
Mochida Pharmaceutical Company. The EPA-E used in this study was 
purified from sardine oi l  as previously reported (4). Each 
gelatin-coated soft capsule weighed 400 mg and comprised ethylesters 
containing 75% eicosapentaenoic acid, 3.B% octadecatraenoic acid, 
6.3% eicosatetraenoic acid (~-3), 6.2% docosahexaenoic acid, and 
0.2% =-tocopherol. EPA-E in such a form is stable for at least 6 
months at 25°C or 40°C, with no change in i ts peroxide value. 
During the experimental period of 16 weeks, the patients ingested 6 
capsules (EPA 1.8 g/day) or 9 capsules (EPA 2.7 g/day) with meals 
(divided in 3 times a day). They consumed an ordinary 3apanese diet 
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(1800-2200 Kcalorie) with average intake of I00 g fish meat, equivalent 
to o.g g EPA. Venous blood samples were obtained after 12 hours of 
fasting at the start of the experiment and 4 weeks after the beginning of 
the study. 
RESULTS AND DISCUSSION 
Aggregation of p la te le ts  general ly involves the release of 
arachidonate from the membrane of the p l a t e l e t  and i t s  oxidat ion to 
TXA 2 (v ia  PGH2) that  signals aggregation to occur. Figure 1 
i l l u s t r a t e s  the release of thromboxane A2, measured as TXB 2, from 
p la te le ts  stimulated to aggregate with various concentrations of collagen 
(2.2, I0,  22, and I00 ~g/ml). Although the percent aggregation tended to 
be l i n e a r l y  related to TXB 2 formation below 50% aggregation, 
aggregations of 50 to g5% produced thromboxane concentrations between 
50 and 500 so the re la t ionsh ip  between aggregation and thromboxane 
generation was not a simple dose-response associat ion. The resu l ts  in 
Figure 1 i l l u s t r a t e  that  p la te le ts  can be stimulated to produce much more 
thromboxane than is needed fo r  aggregation. Although the amounts of 
thromboxane formed increased with increasing concentrations of collagen, 
the percent aggregation reached i t s  l im i t i ng  value with intermediate 
amounts of col lagen. The curve also indicates that  50% aggregation can 
occur with r e l a t i v e l y  l i t t l e  thromboxane release. When both aggregation 
and thromboxane generation was low, there was a more l inear  re la t ionsh ip  
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Fig. 1 Relationship between thromboxane generation and percent 
aggregation for normal subjects. Platelet-rich plasma was 
challenged with different amounts of collagen: (-~-), 2.2 
gg/ml; (-0-) 22 ~g/ml; (-+-), lO ~g/ml; (-a-). I00 ,g/ml; (-*-), 
2.2 ,g/ml, after storage for 2 days. 
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I t  is our collective experience that increasingly stronger stimuli 
for aggregation give more TXB 2 formation even though no further 
aggregation can be detected. Essentially maximal aggregation can be 
achieved in fresh platelet-r ich plasma (PRP) with 30 to 40 ng/ml TXB 2. 
This conclusion can be derived from two different results. When PRP was 
incubated with PGH 2, there was a burst of TXB 2 synthesis which then 
declined (5). When the peak burst of TXB 2 synthesis reached 30 to 40 
ng/ml, maximal aggregation occurred. When results from lO separate 
experiments were pooled, the average concentration of thromboxane that 
was associated with maximal aggregation was 36.2 ± 4.7. Essentially the 
same value was found using the stable analog of PGH2/TXA 2, U-51093 
(9,11-azoprosta-5,13-dien-l-oic acid). This synthetic molecule mimics 
thromboxane A 2 in being a potent stimulator of human platelet 
aggregation (6), and i t  appears to be equipotent to TXA 2 in this regard 
(7). When dose response curves are generated with U-51093, essentially 
maximal aggregation was achieved with 30 to 40 ng/ml (Figure 2), and the 
aggregation response was linear with respect to the agonist only at 
values below 30 ng/ml. The average value of the experiments for the 
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Fig. 2 Dose-response curves with U-51093. The amount of the 
thromboxane-mimetic agent is noted for each curve. 
The above results were useful in evaluating an epidemiological study 
of platelet function in the residents of farming and fishing villages (8) 
that had a small, but s ta t i s t i ca l l y  signif icant reduction in the maximum 
aggregation and TXB 2 formation from pIatelets of subjects who had eaten 
supplemental EPA for 4 weeks. Individuals exhibited a wide range of 
responsiveness to l pg collagen per ml (Figure 3). A linear correlation 
(r = 0.71, y = 1.5 x +8.8) was observed between collagen-induced platelet 
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Table I .  Changes in p latelet  aggregation and TXB 2 formation after 
ingestion of ethyl eicosapentaenoate. 
0 week (before) 4 week (after) 
Platelet aggregation (%) 
Collagen (l.O pg/ml) 
( I .5  ~g/ml) 
TXB 2 formation (ng/ml) 
Collagen (l.O ~g/ml) 
(1.5 pg/ml) 
60 ± 15 45 ± 30*** 
67 ± 12 53 ± 23** 
51 ± 30 33 ± 31"* 
61 ± 29 43 ± 25*** 
** p < O.Ol *** p < O.OOl Mean + S.D. 
aggregation and TXB 2 formation only when the amount of TXB 2 produced 
was less than around 40 ng/ml PRP. No such correlation was noted when 
the production of TXB 2 was over 40 ng/ml PRP (Figure 3). The arrows in 
the f igure indicate that in 31 of the 40 paired cases studied, the 
p late let  function decreased. High levels of TXB 2 were frequently 
decreased with l i t t l e  change in aggregation, and low levels of TXB 2 
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Fig. 3. Changes in p latelet  aggregation and thromboxane formation after 
4 weeks ingestion of EPA-E. Collagen l.O gg/ml)-induced 
plate let  aggregation and thromboxane B 2 formation was 
determined in the patients with thrombotic cardiovasculor 
disorders before and after 4 weeks ingestion of EPA-E ( I .8  or 
2.7 g/day) as described in Materials and Methods. The 
arrows indicate the changes observed for each patient. 
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Results in Figure l approached 70 to 80% aggregation with lO0 to 
150 ng TXB 2 per ml (and 60% with 70 ng/ml), whereas in Figure 2 they 
were 70 to B0% with 30 ng/ml of the TXA 2 analog added and 60% at lO 
ng/ml. In Figure 3, 70 to 80% occurred with 30 to 60 ng TXB2/ml and 
60% at about 25 ng/ml. Our collective experience leads us to emphasize 
the desirabi l i ty of designing platelet function studies with levels of 
stimulating aggregant that are below the maximal value. Recently, the 
complexities of "strong" and "weak" aggregants at threshold and 
supramaximal concentrations were adumbrated extensively (9). By avoiding 
overstimulation of thromboxane formation, we believe that investigators 
can find better correlations between aggregation and TXB 2 formation to 
interpret the effects of antithrombotic regimens. 
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